Pronóstico de los pacientes menores de 50 años
46
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author M
Lin et al.
TABLE 2
Overall and prostatecancer-specificsurvival of patientswith prosta
age, grade, and stage
Overall survival
HR (95% CI )
Prostatecancer-specificsurvival
HR (95% CI )
Gleason 5-7
Gleason 8-10
Gleason 5-7
Gleason 8-10
All stages
* *
Agegroups
35-44
Referent
Referent
Referent
Referent
45-54
1.45 (0.95, 2.22)
0.66 (0.50,0.86)
†
0.80 (0.50,1.27)
0.64 (0.48,0.86)
†
55-64
2.10 (1.38, 3.19)
†
0.71 (0.54,0.92)
†
0.79 (0.50,1.24)
0.58 (0.44,0.77)
†
65-74
3.53 (2.32, 5.37)
†
0.89 (0.69,1.16)
0.92 (0.59, 1.45)
0.60 (0.46,0.80)
†
StagesI and I I
*
Agegroups
35-44
Referent
Referent
Referent
Referent
45-54
6.28 (1.56,25.22)
†
1.03 (0.38,2.81)
2.07 (0.29,14.95) 1.36 (0.33,5.60)
55-64
9.96 (2.49,39.84)
†
1.21 (0.45,3.25)
2.29 (0.32,16.34) 0.98 (0.24,3.95)
65-74
18.25 (4.56,73.02)
†
1.70 (0.64,4.55)
3.27 (0.46,23.29) 1.06 (0.26, 4.25)
Stage I I I
*
Agegroups
35-44
Referent
Referent
Referent
Referent
45-54
††
0.38 (0.18, 0.78)
† ††
0.30 (0.14,0.65)
†
55-64
††
0.49 (0.24, 0.99)
† ††
0.30 (0.14,0.63)
†
65-74
††
0.73 (0.37, 1.47)
††
0.33 (0.16,0.70)
†
StagesIV
*
Agegroups
35-44
Referent
Referent
Referent
Referent
45-54
0.75 (0.47, 1.18)
0.71 (0.52, 0.97)
†
0.65 (0.40,1.06)
†
0.67 (0.49,0.93)
†
55-64
0.79 (0.50, 1.23)
0.73 (0.54, 0.98)
†
0.60 (0.37,0.96)
†
0.61 (0.45,0.84)
†
65-74
0.96 (0.63, 1.52)
0.83 (0.61,1.10)
0.60 (0.38,0.96)
†
0.62 (0.46,0.85)
†
*
